Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease.
研究概览
简要总结
Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments.
Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment.
The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years or above at the time of inclusion;
- •Patients newly diagnosed with acute myeloid leukemia;
- •No contraindication or intolerance to any of the components of the standard chemotherapy by induction (7+3);
- •Patients able to give written informed consent.
排除标准
- •Patients unable to tolerate decubitus position for at least 45 minutes;
- •Any previous neoplasia or other neoplasia simultaneously;
- •Previously treated buy radiotherapy, with bone marrow in the field of radiation;
- •Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before the second FLT-TEP was done.
结局指标
主要结局
To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease.
时间窗: September 2015
次要结局
未报告次要终点
研究者
Dr Éric E Turcotte, MD
Principal Investigator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke